Stifel Nicolaus Lowers Inspire Medical Systems (NYSE:INSP) Price Target to $175.00

Inspire Medical Systems (NYSE:INSP - Get Free Report) had its price target decreased by investment analysts at Stifel Nicolaus from $190.00 to $175.00 in a research report issued to clients and investors on Monday,Benzinga reports. The firm currently has a "hold" rating on the stock. Stifel Nicolaus' target price indicates a potential upside of 10.08% from the company's current price.

A number of other analysts have also commented on INSP. Wells Fargo & Company reduced their price target on shares of Inspire Medical Systems from $198.00 to $195.00 and set an "equal weight" rating for the company in a research note on Tuesday, February 11th. KeyCorp decreased their target price on shares of Inspire Medical Systems from $234.00 to $216.00 and set an "overweight" rating for the company in a research note on Monday, April 21st. Truist Financial lowered their price target on Inspire Medical Systems from $250.00 to $235.00 and set a "buy" rating on the stock in a report on Tuesday, February 11th. Piper Sandler cut their price objective on Inspire Medical Systems from $260.00 to $233.00 and set an "overweight" rating for the company in a report on Monday, February 10th. Finally, Robert W. Baird lowered their target price on Inspire Medical Systems from $252.00 to $248.00 and set an "outperform" rating on the stock in a report on Tuesday, February 11th. Three analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company's stock. Based on data from MarketBeat, Inspire Medical Systems currently has a consensus rating of "Moderate Buy" and a consensus price target of $218.90.

Inspire Medical Systems Stock Up 0.5 %

Shares of NYSE INSP traded up $0.77 on Monday, reaching $158.97. 315,939 shares of the company's stock traded hands, compared to its average volume of 583,830. The business's 50 day simple moving average is $162.86 and its two-hundred day simple moving average is $181.43. Inspire Medical Systems has a 12 month low of $123.00 and a 12 month high of $257.40. The company has a market cap of $4.73 billion, a price-to-earnings ratio of 91.89, a price-to-earnings-growth ratio of 2.86 and a beta of 1.39.

Inspire Medical Systems (NYSE:INSP - Get Free Report) last announced its quarterly earnings data on Monday, February 10th. The company reported $1.15 EPS for the quarter, beating the consensus estimate of $0.74 by $0.41. Inspire Medical Systems had a net margin of 6.67% and a return on equity of 8.19%. Analysts forecast that Inspire Medical Systems will post 2.16 earnings per share for the current fiscal year.

Insider Buying and Selling at Inspire Medical Systems

In other Inspire Medical Systems news, CTO John Rondoni sold 583 shares of the stock in a transaction dated Tuesday, February 11th. The stock was sold at an average price of $170.49, for a total value of $99,395.67. Following the completion of the sale, the chief technology officer now directly owns 10,424 shares in the company, valued at approximately $1,777,187.76. This trade represents a 5.30 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Randy Ban sold 25,584 shares of the stock in a transaction that occurred on Thursday, February 13th. The shares were sold at an average price of $183.50, for a total transaction of $4,694,664.00. Following the completion of the transaction, the insider now directly owns 7,259 shares of the company's stock, valued at $1,332,026.50. The trade was a 77.90 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 4.10% of the company's stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Dragoneer Investment Group LLC acquired a new position in shares of Inspire Medical Systems in the fourth quarter worth about $161,486,000. TimesSquare Capital Management LLC acquired a new position in Inspire Medical Systems in the 4th quarter worth about $80,419,000. Congress Asset Management Co. raised its holdings in Inspire Medical Systems by 3,943.6% in the 1st quarter. Congress Asset Management Co. now owns 307,555 shares of the company's stock worth $48,987,000 after purchasing an additional 299,949 shares during the period. Marshall Wace LLP boosted its position in Inspire Medical Systems by 1,775.3% during the fourth quarter. Marshall Wace LLP now owns 277,131 shares of the company's stock worth $51,375,000 after purchasing an additional 262,353 shares in the last quarter. Finally, Raymond James Financial Inc. acquired a new stake in Inspire Medical Systems in the fourth quarter valued at approximately $47,604,000. 94.91% of the stock is currently owned by institutional investors and hedge funds.

Inspire Medical Systems Company Profile

Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA.